Genovyn

Genovyn is an AI-enabled biotechnology company focused on accelerating therapeutic discovery and development through the integration of artificial intelligence, translational science, and precision biology. Operating under a unique hub-and-spoke business model, the company advances its pipeline through therapeutically focused, agile subsidiaries known as "Vyns" (such as Tripsovyn, Panovyn, and Imunovyn), which are supported by its proprietary data intelligence arm, Datavyn. Genovyn's lead program, Tripsovyn, is in preclinical development for triple-negative breast cancer (TNBC) and utilizes three novel small molecules and four drug combinations designed to act independently of traditional hormone and HER2 receptor pathways. The company is also developing companion diagnostics (CDx) to enable personalized patient stratification and match individuals with the most effective therapies. Genovyn's strategy centers on advancing candidates through Phase 1 clinical trials before partnering with major pharmaceutical companies for late-stage development and commercialization.